跳轉至內容
Merck
全部照片(1)

重要文件

C2180000

桂利嗪

European Pharmacopoeia (EP) Reference Standard

同義詞:

1-反式-肉桂基-4-二苯基甲基哌嗪

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C26H28N2
CAS號碼:
分子量::
368.51
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

cinnarizine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

C1CN(CCN1C\C=C\c2ccccc2)C(c3ccccc3)c4ccccc4

InChI

1S/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+

InChI 密鑰

DERZBLKQOCDDDZ-JLHYYAGUSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Cinnarizine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

相關產品

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Anne T Larsen et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 48(1-2), 339-350 (2012-11-28)
The in vivo performance of self-nanoemulsifying drug delivery systems (SNEDDSs) with different in vitro physicochemical properties were determined with the purpose of elucidating the parameters determining the in vivo performance of SNEDDSs. The in vitro characterisation included the use of
P Y Cezarino et al.
Climacteric : the journal of the International Menopause Society, 14(4), 492-496 (2011-03-24)
To evaluate the effectiveness and safety of cinnarizine in the treatment of menopausal symptoms. A total of 100 climacteric and symptomatic women participated in a double-blind, placebo-controlled study. They were divided into two groups of the same size: Gcin, intake
Mohamed A Alhnan et al.
International journal of pharmaceutics, 416(1), 55-60 (2011-06-18)
Poorly water soluble basic drugs are very sensitive to pH changes and following dissolution in the acidic stomach environment tend to precipitate upon gastric emptying, which leads to compromised or erratic oral bioavailability. In this work, we show that the
Amnon Gil et al.
Clinical neuropharmacology, 35(1), 37-39 (2011-12-06)
The objective of the study was to compare the efficacy of transdermal scopolamine and cinnarizine in the prevention of seasickness and their adverse reactions. Seventy-six naval crew members participated in a double-blind, randomized, crossover study. On 2 voyages, they were
Tri-Hung Nguyen et al.
Journal of controlled release : official journal of the Controlled Release Society, 153(2), 180-186 (2011-04-19)
This study is the first to demonstrate the ability of nanostructured liquid crystal particles to sustain the absorption of a poorly water soluble drug after oral administration. Cubic (V(2)) liquid crystalline nanostructured particles (cubosomes) formed from phytantriol (PHY) were shown

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務